ACTA1 and Hepatic fibrosis: Resistance to fibrosis was compromised in FVB mice receiving weekly CLO injections, which developed significant hepatic fibrosis, as evidenced by increase in collagen deposition, histological signs of bridging fibrosis, and increase in HSC activation marker α-SMA, compared to controls treated with TAA and vehicle [phosphate-buffered saline (PBS)]-loaded liposomes (Supplementary Fig. 5).